Qualitative disorders of platelets and megakaryocytes

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 8, 2005, Pages 1773-1782

  Nurden, Alan T ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Activation pathways; Gene therapy; Inherited disorder; Integrin; Megakaryocyte; Platelet

Indexed keywords

INTEGRIN; VON WILLEBRAND FACTOR;

BERNARD SOULIER DISEASE; CHEDIAK HIGASHI SYNDROME; CONFERENCE PAPER; GENE; GENE MUTATION; GENE THERAPY; GENETIC CORRELATION; GENETIC DISORDER; GLANZMANN DISEASE; HUMAN; MEGAKARYOCYTE; MYELOFIBROSIS; MYH9 GENE; OCULAR ALBINISM; PRIORITY JOURNAL; SCOTT SYNDROME; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME;

BERNARD-SOULIER SYNDROME; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; COAGULANTS; GENE THERAPY; HUMANS; INTEGRINS; MEGAKARYOCYTES; MODELS, BIOLOGICAL; PLATELET AGGREGATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; THROMBASTHENIA; THROMBOCYTOPENIA; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 28344439804     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01428.x     Document Type: Conference Paper

References (100)

1. Nurden A, Nurden P. Inherited disorders of platelet function. In: Michaelson AD, ed. Platelets. San Diego: Academic Press, 2003: 681-700.
2. Nurden AT, George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Vth Edition. Philadelphia: Lippincott, Williams & Wilkins, 2005: (In Press).
3. Nurden AT, Caen JP. Specific roles for surface membrane glycoproteins in platelet function. Nature 1975; 255: 720-2.
4. Patel D, Vaananen H, Jirouskova M, Hoffmann T, Bodian C, Coller BS. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 2003; 101: 929-36.
5. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-70.
6. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL III, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-25.
7. Milet-Marsal S, Breillat C, Peyruchaud O, Nurden P, Combrié R, Nurden AT, Bourre F. Analysis of the amino acid requirement for a normal αIIbβ3 maturation at αIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 655-62.
8. Gidwitz S, Temple B, White GC II. Mutations in and near the second calcium-binding domain of integrin αIIb affect the structure and function of integrin αIIbβ3. Biochem J 2004; 379: 449-59.
9. McHugh KP, Hodilvala-Dilke K, Zheng M-H, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105: 433-40.
10. Reynolds AR, Reynold LE, Nagel TE, Lively JC, Robinson SD, Hicklin DJ, Bodary SC, Hodivala-Dilke KM. Elevated Flk1 (Vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin- deficient mice. Cancer Res 2004; 64: 8643-50.
11. Xiao T, Takagi J, Coller BS, Wang J-H, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
12. Ruiz C, Liu C-Y, Sun Q-H, Sigaud-Fiks M, Fressinaud E, Muller JY, Nurden P, Nurden AT, Newman PJ, Valentin N. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (αIIbβ3) integrin receptor locked in a high affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001; 98: 2432-41.
13. McDowall A, Inwald D, Leitinger B, Jones A, Liesner R, Klein N, Hogg N. A novel form of integrin dysfunction involving β1, β2, and β3 integrins. J Clin Invest 2003; 111: 51-60.
14. Shpilberg O, Rabi I, Schiller K, Walden R, Harats D, Tyrrell KS, Coller B, Seligsohn U. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein αIIbβ3 (GPIIb/IIIa) and αvβ3 receptors are not protected from atherosclerosis. Circulation 2002; 105: 1044-8.
15. Jacobin MJ, Laroche-Traineau J, Little M, Keller A, Peter K, Welschof M, Nurden A, Clofent Sanchez G. Human IgG monoclonal anti-αIIbβ3-binding fragments derived from immunized donors using phage display. J Immunol 2002; 168: 2035-45.
16. Poon MC, d'Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A, Huth-Kuehne A, Morfini M. International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-103.
17. Lisman T, Adelmaier J, Heijnen HFG, De Groot PG. Recombinant factor Vila restores aggregation of αIIbβ3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-7.
18. Wilcox DA, White GC II. Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J Thromb Haemost 2003; 1: 2300-11.
19. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.
20. Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004; 16: 15-24.
21. Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, Lopez JA, Walsh PN. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibα on the activated platelet. J Biol Chem 2004; 279: 49323-9.
22. Strassel C, Pasquet J-M, Alessi M-C, Juhan-Vague I, Chambost H, Combrié R, Nurden P, Bas MJ, De La Salle C, Cazenave JP, Lanza F, Nurden AT. A novel missense mutation shows that GPIbβ has a dual role in controlling the processing and stability of the platelet GPIb-IX adhesion receptor. Biochemistry 2003; 42: 4452-62.
23. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: The Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-8.
24. Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbα is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model. Exp Hematol 2002; 30: 352-60.
25. Poujol C, Ramakrishnan V, Deguzman F, Nurden AT, Phillips DR, Nurden P. Ultrastructural analysis of megakaryocytes in GPV knockout mice. Thromb Haemost 2000; 84: 312-8.
26. Kato K, Martinez C, Russell S, Nurden P, Nurden A, Fiering S, Ware J. Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size. Blood 2004; 104: 2339-44.
27. Uff S, Clemetson JM, Harrison T, Clemetson KJ, Emsley J. Crystal structure of the platelet glycoprotein IbαN-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem 2002; 277: 35657-63.
28. Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, Somers WS, Mosyak L. Crystal structure of the wild-type Von Willebrand factor A1-glycoprotein Ibαcomplex reveals conformation differences with a complex bearing Von Willebrand disease mutations. J Biol Chem 2004; 279: 23327-34.
29. Ware J, Russell SR, Marchese P, Murata M, Mazzucato M, De Marco L, Ruggeri ZM. Point mutation in a leucine-rich repeat of platelet glycoprotein Ibα resulting in the Bernard-Soulier syndrome. J Clin Invest 1993; 92: 1213-20.
30. Matsubara Y, Murata M, Sugita K, Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ibα, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost 2003; 1: 2198-205.
31. Othman M, Elbatarny HS, Notley C, Lavender LF, White H, Byrne CD, O'Shaughnessy DF, Lillicrap DP. Identification and functional characterization of a novel 27bp deletion in the macroglycopeptide-coding region of the GPIbα gene resulting in platelet-type von Willebrand disease. Blood 2004; 104: (abstract 1023).
32. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR. Targeting platelet GPIbα transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbβ and GPIX. J Thromb Haemost 2004; 2: 1989-97.
33. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103: 390-8.
34. Nurden P, George JN, Nurden AT. Inherited thrombocytopenias. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, Vth Edition. Philadelphia: Lippincott, Williams & Wilkins, 2005: (In Press).
35. Savoia A, Balduini CL, Savino M, Noris P, Del Vecchio M, Perrotta S, Belletti S, Poggi V, Iolascon A. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97: 1330-5.
36. Kelly RG, Jerome-Majewska LA, Papaioannou VE. The del 22q11.2 gene Tbx1 regulates branchiomeric myogenesis. Hum Mol Genet 2004; 13: 2829-40.
37. Kato T, Kosaka K, Kimura M, Imamura S, Yamada O, Iwai K, Ando M, Joh-o K, Kuroe K, Ohtake A, Takao A, Momma K, Matsuoka R. Thrombocytopenia in patients with 22q11.2 deletion syndrome and its association with glycoprotein Ibβ. Genet Med 2003; 5: 113-9.
38. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 2000; 26: 103-5.
39. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Braker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA. Nonmuscle myosin heavy chain IIa mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly, and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-45.
40. Balduini C, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM, Savoia A. Italian Gruppo di Studio delle Piastrine. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppoe di Studio delle Piastrine. Haematologica 2003; 88: 582-92.
41. Hu A, Wang F, Sellers JR. Mutations in human nonmuscle myosin UA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function. J Biol Chem 2002; 277: 46512-7.
42. Marigo V, Nigro A, Pecci A, Montanaro D, Di Stazio M, Balduini CL, Savoia A. Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics 2004; 83: 1125-33.
43. Toren A, Rozenfeld-Granot G, Heath KE, Amariglio N, Rocca B, Crosson J, Epstein CJ, Laghi F, Landolfi R, Carsson LE, Argraves S, Bizzaro N, Moxey-Mims M, Brok-Simoni F, Martignetti JA, Greinacher A, Rechavi G. MYH9 spectrum of autosomal-dominant giant platelet syndromes: unexpected association with fibulin-1 variant-D inactivation. Am J Hematol 2003; 74: 254-62.
44. Song W-J, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende JC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gerwitz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 29: 166-75.
45. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002; 99: 1364-72.
46. Sun L, Mao G, Rao AK. Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and plekstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 2004; 103: 948-54.
47. Grossfeld PD, Mattina T, Lai Z, Favier R, Jones KL, Cotter F, Jones C. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet 2004; 129: 51-61.
48. Raslova H, Komura E, Le Couédic JP, Larbret F, Debili N, Feunteun J, Danos O, Albagli O, Vainchenker W, Favier R. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest 2004; 114: 77-84.
49. Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999; 96: 3133-6.
50. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K. C-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 139-46.
51. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, Ueda R. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103: 4198-200.
52. Gandhi MJ, Cummings CL, Drachman JG. FLJ14813 missense mutation; a candidate for autosomal dominant thrombocytopenia on human chromosome 10. Hum Hered 2003; 55: 66-70.
53. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000; 26: 397-8.
54. Ballmaier M, Schulze H, Cremer M, Folman CC, Strauss G, Weite K. Defective c-Mpl signaling in the syndrome of thrombocytopenia with absent radii. Stem Cells 1998; 16: 177-84.
55. Letestu R, Vitrat N, Massé A, Le Couadic JP, Lazar V, Rameau P, Wendling F, Vuillier J, Boutard P, Plouvier E, Plasse M, Favier R, Vainchenker W, Debili N. Existence of a differential blockage at the stage of amegakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 2000; 95: 1633-41.
56. Nichols KE, Crispino JD, Poncz M, White JG, Orkin SH, Maris JM, Weiss MJ. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000; 24: 266-70.
57. Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, Minner K, Hoylaerts MF, Vermylen J, Van Geet C. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001; 98: 85-92.
58. Freson K, Matthijs G, Thys C, Marien P, Hoylaerts MF, Vermylen J, Van Geet C. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet 2002; 11: 147-52.
59. Yu C, Niakan KK, Matsushita M, Stamatocyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100: 2040-5.
60. Balduini CL, Pecci A, Loffredo G, Izzo P, Noris P, Grosso M, Bergamaschi G, Rosti V, Magrini U, Ceresa IF, Conti V, Poggi V, Savoia A. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost 2004; 91: 129-40.
61. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 1628-36.
62. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, Goodman DS, Baumgartner HR. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296-319.
63. Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A, Kroemer HK. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 2004; 104: 3603-10.
64. Huizing M, Anikster Y, Gahl WA. Hermansky-Pudlak syndrome and Chediak-Higashi syndrome: disorders of vesicle formation and trafficking. Thromb Haemost 2001; 98: 233-45.
65. Li W, Zhang Q. Oiso N, Novak EK, Rusiniak ME, Gautam R, Chintala S, O'Brien EP, Zhang Y, Roe BA, Elliott RW, Eicher EM, Liang P, Kratz C, Legius E, Spritz RA, O'Sullivan TN, Copeland NG, Jenkins NA, Swank RT. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 2003; 35: 84-9.
66. Dell'Angelica EC. The building BLOC(k)s of lysosomes and related organelles. Curr Opin Cell Biol 2004; 16: 458-64.
67. Ward DM, Shiflett SL, Kaplan J. Chediak-Higashi syndrome: a clinical and molecular view of a rare lyosomal storage disorder. Curr Mol Med 2002; 2: 469-77.
68. Huynh C, Roth D, Ward DM, Kaplan J, Andrews NW. Defective lysosonial exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. Proc Natl Acad Sci USA 2004; 101: 16795-800.
69. Novak EK, Gautam R, Reddington M, Collinson LM, Copeland NG, Jenkins NA, McGarry MP, Swank RT. The regulation of platelet dense granules by Rab27a in the ashen mouse, a model of Hermansky-Pudlak and Griscelli syndromes, is granule-specific and dependent on genetic background. Blood 2002; 100: 128-35.
70. Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Defective α-granule production in megakaryocytes from gray platelet syndrome. Ultrastructural studies on bone-marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 1981; 102: 10-9.
71. Hyman T, Huizing M, Blumberg PM, Falik-Zaccai TC, Anikster Y, Gahl WA. Use of a cDNA microarray to determine molecular mechanisms involved in grey platelet syndrome. Br J Haematol 2003; 122: 142-9.
72. Nurden P, Jandrot-Perrus M, Combrié R, Winckler J, Arocas V, Lecut C, Pasquet JM, Kunicki TJ, Nurden AT. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood 2004; 104: 107-14.
73. Schmitt A, Joualt H, Guichard J, Wendling F, Drouin A, Cramer E. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000; 96: 1342-7.
74. Briquet-Laugier V, Lavenu-Bombled C, Schmidtt A, Le Bouef M, Uzan G, Dubart-Kupperschmitt A, Rosa JP. Probing platelet factor 4 α-granule targeting. J Thromb Haemost 2004; 2: 2231-40.
75. Kahr WHA, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, Podor TJ, Rivard GE, Hayward CP. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-65.
76. Sheth PM, Kahr WHA, Haq MA, Veljkovic K, Rivard GE, Hayward CPM. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb Haemost 2003; 90: 293-8.
77. McKay H, Derome F, Haq MA, Whittaker S, Arnold E, Adam F, Heddle NM, Rivard GE, Hayward CP. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104: 159-65.
78. Holtkotter O, Nieswandt B, Smyth N, Muller W, Hafner M, Schulte V, Krieg T, Eckes B. Integrin α2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002; 277: 10789-94.
79. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003; 102: 1701-7.
80. Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface. Blood 2004; 104: 1350-5.
81. Joutsi-Korhonen L, Smethurst PA, Rankin A, Gray E, Ijsseldijk M, Onley CM, Watkins NA, Williamson LM, Goodall AH, de Groot PG, Farndale RW, Ouwehand WH. The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood 2003; 101: 4372-9.
82. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden AT. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its effect on glycoprotein IIb-IIIa function. J Clin Invest 1995; 95: 1612-22.
83. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
84. 12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-83.
85. Oury C, Toth-Zsambokil E, Van Geet C, Thys C, Wei L, Nilius B, Vermylen J, Hoylaerts MF. A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue. J Biol Chem 2000; 275: 22611-4.
86. 60 to Leu mutation. J Clin Invest 1996; 97: 949-56.
87. Higuchi W, Fuse I, Hattori A, Aizawa Y. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb Haemost 1999; 82: 1528-31.
88. Fuse I, Higuchi W, Mito M, Aizawa Y. DDAVP normalized the bleeding time in patients with congenital platelet TXA2 receptor abnormality. Transfusion 2003; 43: 563-7.
89. Rao AK. Inherited defects in platelet signaling mechanisms. J Thromb Haemost 2003; 1: 671-81.
90. Gabbeta J, Vaidyula VR, Dhanasekaran N, Rao AK. Human platelet Gαq deficiency is associated with decreased Gαq gene expression in platelets but not neutrophils. Thromb Haemost 2002; 87: 129-33.
91. Mao GF, Vaidyula VR, Kunapuli SP, Rao AK. Lineage-specific defect in gene expression in human platelet phospholipase C-β2 deficiency. Blood 2002; 99: 905-11.
92. i signaling in the platelets of a patient with a chronic bleeding disorder. Blood 2003; 101: 4828-35.
93. Burns S, Cory GO, Vainchenker W, Thatcher AJ. Mechanisms of WASp-mediated hematologic and immunologic disease. Blood 2004; 104: 3454-62.
94. Jin Y, Mazza C, Christie JR. Mutations of the Wiskott-Aldrich syndrome protein (WASp): hot spots, effect on translation and transcription, and genotype/phenotype correlation. Blood 2004; 104: 1733-9.
95. Devriendt K, Kim AS, Mathijs G, Prints SG, Schwartz M, Van Den Oord JJ, Verhoef GE, Boogaerts MA, Fryns JP, You D, Rosen MK, Vandenberghe P. Constitutively activating mutation in WASp causes X-linked severe congenital neutropenia. Nat Genet 2001; 27: 313-7.
96. Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA. Bucher-Laurent S, Delenda C, Vainchenker W, Danos O, Galy A. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 2005; 12: 597-606.
97. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by a defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636: 119-28.
98. Sims P, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost 2001; 86: 266-75.
99. 2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells. Biochemistry 1999; 38: 10092-8.
100. D'Andrea G, Colaizzo D, Vecchione G, Grandone E, Di Minno G, Margaglione M. Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost 2002; 87: 1034-42.